ArticleBriefings in bioinformatics2026
MRDsteer: quality-aware AI-driven closed-loop optimization enhances ctDNA-based minimal residual disease detection.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Accurate identification of ultra-low-frequency tumor-derived variants is critical for circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) profiling. However, current ctDNA analysis workflows largely operate as predefined, sequential pipelines without explicit mechanisms for continuous monitoring of variant-calling performance or adaptive control, thereby limiting detection stability in genomically heterogeneous regions. To address this limitation, we developed MRDsteer, an autonomous closed-loop agent driven by artificial intelligence (AI). MRDsteer monitors the analytical reliability of variant calling during the analysis process using multidimensional quality metrics, such as filtration ratio and strand bias. When the estimated reliability falls below an actionable threshold, MRDsteer triggers localized re-calling only in high-risk genomic regions, instead of repeating the entire analysis. In this way, MRDsteer provides closed-loop control by continuously assessing variant-calling reliability and applying targeted intervention when needed. Comparative analyses in simulated and real-world datasets showed that MRDsteer improved the stability and sensitivity of ctDNA variant detection. Under challenging conditions, including ultra-low variant allele frequencies, MRDsteer demonstrated improved detection performance compared with representative baseline methods. In clinical cohorts, MRDsteer improved ctDNA-based MRD stratification and strengthened progression-free survival separation in the K438 cohort, including both non-small cell lung cancer (NSCLC) and nasopharyngeal carcinoma (NPC) subgroups. These results suggest that MRDsteer may provide a robust and clinically useful computational strategy for sensitive MRD detection and longitudinal ctDNA monitoring. https://github.com/aAT0047/MRDsteer.git.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.